— Know what they know.
Not Investment Advice
Also trades as: 0I5P.L (LSE) · $vol 0M

CBAY NASDAQ

CymaBay Therapeutics, Inc.
1W: +0.1% 1M: +0.8% 3M: +46.2% 1Y: +262.9% 3Y: +579.5% 5Y: +172.2%
$32.48
Last traded 2024-03-25 — delisted
NASDAQ · Healthcare · Biotechnology · $3.7B mcap · 97M float · 4.31% daily turnover

Cash Flow Trends

Operating Cash Flow
-$73M +13.7% ▲
Capital Expenditures
$445K -200.7% ▼
5Y CAGR: -3.4%
Free Cash Flow
-$73M +13.4% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$186M +276.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2019FY2020FY2021FY2022FY2023
— Operating Activities —
Net Income-$103M-$51M-$90M-$106M-$105M
Depreciation & Amort.$572K$632K$688K$710K$681K
Stock-Based Comp.$10M$7M$10M$10M$15M
Change in Working Capital-$4M-$2M$6M-$2M$6M
Other Non-Cash Items$910K-$104K$3M$14M$14M
Operating Cash Flow-$98M-$45M-$69M-$84M-$73M
— Investing Activities —
Capital Expenditures-$315K-$21K-$87K-$148K-$445K
Acquisitions (Net)-$2M-$104K$637K-$874K-$8M
Investment Purchases-$291M-$176M-$78M-$175M-$306M
Investment Sales$257M$224M$127M$129M$220M
Other Investing$2M$104K-$637K$874K$8M
Investing Cash Flow-$34M$48M$49M-$46M-$87M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$108M$92K$118M$25M$346M
Financing Cash Flow$108M$92K$118M$25M$346M
Net Change in Cash-$24M$3M$98M-$106M$186M
Cash End of Period$25M$28M$126M$20M$207M
Free Cash Flow-$98M-$45M-$70M-$84M-$73M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms